33 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400 Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
ADTRAN (ADTN) Unveils FSP 3000 M-Flex800 for Network Operators https://www.zacks.com/stock/news/2245572/adtran-adtn-unveils-fsp-3000-m-flex800-for-network-operators?cid=CS-ZC-FT-analyst_blog|company_news_tech_sector-2245572 Mar 25, 2024 - ADTRAN (ADTN) FSP3000 M-Flex800 leverages ZR and ZR+ pluggable optics and empowers operators to match high-capacity connectivity needs across a diverse range of applications.
Looking for a Growth Stock? 3 Reasons Why M?nchener R?ckversicherungs-Gesellschaft (MURGY) is a Solid Choice https://www.zacks.com/stock/news/2242390/looking-for-a-growth-stock-3-reasons-why-m-nchener-r-ckversicherungs-gesellschaft-murgy-is-a-solid-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2242390 Mar 18, 2024 - M?nchener R?ckversicherungs-Gesellschaft (MURGY) possesses solid growth attributes, which could help it handily outperform the market.
Cantor sees strong year ahead for oncology M&A https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says?source=feed_sector_healthcare Mar 10, 2024 - Cantor Fitzgerald sees a strong year for oncology M&A as major drugmakers look to replenish pipelines ahead of steep patent cliffs for top-selling products. Read more here.
M/I Homes: There Are Better Alternatives In The Homebuilding Industry https://seekingalpha.com/article/4675859-mi-homes-there-are-better-alternatives-in-the-homebuilding-industry?source=feed_all_articles Mar 04, 2024 - M/I Homes has seen a significant increase in its stock price, outperforming the broader market over past 12-month period. See why I'm neutral on MHO stock.
Minneapolis company that provides services for M&A deals makes another acquisition of its own https://www.startribune.com/datasite-buys-swiss-company-sherpany-ma-services/600346740/ Feb 28, 2024 - Datasite is acquiring Sherpany, a provider software to manage board room meetings and communication.
Macy's (M) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/27/macys-m-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 27, 2024 - M earnings call for the period ending December 31, 2023.
Macy's (M) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates https://www.zacks.com/stock/news/2232570/macy-s-m-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2232570 Feb 27, 2024 - While the top- and bottom-line numbers for Macy's (M) give a sense of how the business performed in the quarter ended January 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Macy's, Lowe's Beat in Q4; Durable Goods Lower https://www.zacks.com/stock/news/2232544/macy-s-lowe-s-beat-in-q4-durable-goods-lower?cid=CS-ZC-FT-ahead_of_wall_street-2232544 Feb 27, 2024 - We have some grist for the trading mill ahead of the opening bell, but it's not likely to cause any meaningful tremors from this vantage point.
Macy's (M) Suffers a Larger Drop Than the General Market: Key Insights https://www.zacks.com/stock/news/2228893/macy-s-m-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2228893 Feb 20, 2024 - In the most recent trading session, Macy's (M) closed at $19.26, indicating a -1.03% shift from the previous trading day.

Pages: 1234

Page 1>